Hyperkeratotic hand-foot syndrome

  • 15min
  • May. 2022
  • Supported by
  • La Roche-Posay

Therapeutic classes inducing this adverse event
BRAF inhibitor, Antiangiogenic agent

Hyperkeratotic hand-foot syndrome
Hyperkeratosis of support points
Hyperkeratosis of support points

Browse for more adverse events